News
-
-
PRESS RELEASE
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Formycon AG invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences. Management Board to discuss key financial figures and recent uplisting to the Prime Standard of Frankfurt Stock Exchange -
-
PRESS RELEASE
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Formycon receives positive CHMP opinion for FYB203, a biosimilar candidate to Eylea, under tradenames AHZANTIVE and Baiama. Approval decision by European Commission expected in January 2025 -
-
PRESS RELEASE
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Formycon AG announces positive CHMP opinion from EMA for Aflibercept-Biosimilar FYB203 (AHZANTIVE®/ Baiama®) as a treatment for retinal diseases. Market approval expected by January 2025 -
-
PRESS RELEASE
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Formycon extends CEO contract until 2027. Receives admission to trading in Frankfurt Stock Exchange's Prime Standard. Company's biosimilars contribute to healthcare accessibility and cost reduction -
-
